Amerigen Pharmaceuticals Inc. FDA Inspection Record
Amerigen Pharmaceuticals Inc. is an FDA-inspected facility (FEI 3008849302) located in Lyndhurst, NJ, US. RegDataLab tracks 2 FDA inspections at this facility.
What FDA found at this site
- Latest inspection
- Jan 18, 2019: No Action Indicated (NAI)
- Inspections on record
- 2 (1 VAI, 1 NAI)
- Last OAI inspection
- None on record
- Warning letters
- None matched to this FEI. Many letters do not state an FEI: search warning letters by company name
- Recalls as the recalling firm
- 3, latest Feb 19, 2019
- Import refusals
- 1
Inspections and what FDA cited
| Date | Result | What FDA cited |
|---|---|---|
| Jan 18, 2019 | No Action Indicated (NAI) | No citations listed |
| Jul 27, 2017 | Voluntary Action Indicated (VAI) | Failure to develop written procedures (21 CFR 314.80(b)) |
Recalls
| Date | Class | Recall | Product and reason |
|---|---|---|---|
| Feb 19, 2019 | Class III | D-0516-2019 | Temozolomide Capsules, 5 mg, packaged in a) 5-count bottle (NDC 43975-252-05) b) 14-count… Failed dissolution specifications |
| Dec 20, 2018 | Class III | D-0344-2019 | Temozolomide Capsules, 20 mg, packaged in a a) 5-count (NDC 43975-253-05) and b) 14 count… and 1 more product Failed Dissolution Specifications |
| Oct 5, 2018 | Class III | D-0249-2019 | Temozolomide capsules, 20 mg, packaged in a) 5-count bottle(NCD 43975-253-05), b) 14-count… Failed dissolution specifications: Out-of-Specification dissolution results obtained during stability testing. |
FDA record score
2 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.
1 record behind this number
| Record | Date | Points x age weight | Adds |
|---|---|---|---|
| Inspection classified VAI | Jul 27, 2017 | 6 x 0.25 | 1.5 |
When each source was last refreshed
| Records | Last refreshed | Source as of | Status |
|---|---|---|---|
| Inspections | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Inspection citations | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions (warning letters, injunctions and other action types) | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
| Warning letter text | Nov 16, 2026 | Newest record Nov 10, 2026 | Current |
| Recalls (Enforcement Report) | Nov 16, 2026 | Newest record Nov 11, 2026 | Current |
| Form 483s and inspection documents | Nov 13, 2026 | Newest record Nov 12, 2026 | Current |
| Import refusals | Nov 15, 2026 | Newest record Nov 5, 2026 | Current |
Reviewing Amerigen Pharmaceuticals Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Amerigen Pharmaceuticals Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Facility details
- Company
- Amerigen Pharmaceuticals Inc.
- Location
- Lyndhurst, NJ (US)
- Source
- inspections